Steven Cohen's URGN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.53 M shares of UroGen Pharma Ltd. (URGN) worth $56.14 M, representing 0.06% of the portfolio. First purchased in 2018-Q3, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in URGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 1.53 M shares. Largest reduction occurred in Q4 2024, reducing 1.19 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's UroGen Pharma (URGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly UroGen Pharma (URGN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +1.53 M | New Buy | 1.53 M | $36.80 |
| Q3 2025 | -168,779 | Sold Out | 0 | $0.00 |
| Q2 2025 | -67,227 | Reduce 28.49% | 168,779 | $13.70 |
| Q1 2025 | -81,108 | Reduce 25.58% | 236,006 | $11.06 |
| Q4 2024 | -1.19 M | Reduce 78.95% | 317,114 | $10.65 |
| Q3 2024 | -942,631 | Reduce 38.49% | 1.51 M | $12.70 |
| Q2 2024 | +1.34 M | Add 120.25% | 2.45 M | $16.78 |
| Q1 2024 | +986,020 | Add 782.56% | 1.11 M | $15.00 |
| Q4 2023 | -81,733 | Reduce 39.35% | 126,000 | $15.00 |
| Q3 2023 | +207,733 | New Buy | 207,733 | $14.01 |
| Q1 2020 | -222,024 | Sold Out | 0 | $0.00 |
| Q4 2019 | +164,222 | Add 284.11% | 222,024 | $33.37 |
| Q3 2019 | +290 | Add 0.50% | 57,802 | $23.82 |
| Q2 2019 | -206,087 | Reduce 78.18% | 57,512 | $35.94 |
| Q1 2019 | +198,599 | Add 305.54% | 263,599 | $36.94 |
| Q4 2018 | +12,954 | Add 24.89% | 65,000 | $43.06 |
| Q3 2018 | +52,046 | New Buy | 52,046 | $47.23 |
Steven Cohen's UroGen Pharma Investment FAQs
Steven Cohen first purchased UroGen Pharma Ltd. (URGN) in Q3 2018, acquiring 52,046 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held UroGen Pharma Ltd. (URGN) for 17 quarters since Q3 2018.
Steven Cohen's largest addition to UroGen Pharma Ltd. (URGN) was in Q2 2026, adding 1,525,549 shares worth $56.14 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,525,549 shares of UroGen Pharma Ltd. (URGN), valued at approximately $56.14 M.
As of the Q2 2026 filing, UroGen Pharma Ltd. (URGN) represents approximately 0.06% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in UroGen Pharma Ltd. (URGN) was 2,449,277 shares, as reported at the end of Q2 2024.